The synthesis and structure–activity relationships of a novel aryl uracil series which contains a fused 5, 6-bicyclic ring unit for HCV NS5B inhibition is described. Several analogs display replicon cell culture potencies in the low nanomolar range along with excellent rat pharmacokinetic values.